Bausch Health Value Stock - Dividend - Research Selection
Bausch Health Companies Inc.
ISIN: CA0717341071, WKN: A2JQ1X
Market price: 23,06 USD
Bausch Health Companies Inc. Fundamental data and company key figures of the share
| Annual reports in USD | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | 23-02-2020 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | 1.501.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | -503.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | 998.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | 1.063.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | 33.863.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | -1.788.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | -5,080 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | 704.200.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | 8.601.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | BHC |
| Market Capitalization | 16.238.852.096,00 USD |
| Country | Canada |
| Indices | S&P/TSX 60 |
| Sectors | Pharma |
| Raw Data Source | US GAAP in Millionen USD |
| Stock Split | 2000-10-16,2.0000/1.0000; 2000-10-05,2.000000/1.000000; 2000-01-20,2.0000/1.0000; 1996-01-17,3.0000/1.0000 |
| Internet | www.valeant.com |
Description of the company
Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company is engaged in the development and commercialization of a range of generics, generic and branded products, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgery devices and aesthetic devices). It operates through two segments: developed markets and emerging markets. The Developed Markets segment focuses on the areas of dermatology, neurology, gastrointestinal diseases and ophthalmology. The Emerging Markets segment focuses primarily on branded generics, OTC products and medical devices. The pharmaceutical products include Xifaxan, Solodyn and Glumetza. OTC products include Preservision, Biotrue and Boston. Other generics include latanoprost and metronidazole. The ophthalmic products include intraocular lenses such as Akreos, enVista, Crystalens and Trulign.